Alan F Schatzberg

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 3

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 2.3

ph-index = 5

Forward Citations = 105(Granted Patents)

Company Filing History:

8 out of 5,307

Leland Stanford Junior University

patents

3 out of 130

Corcept Therapeutics Incorporated

Years Active: 2000-2016

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9234242 - Methods for treating depression using NCAM peptide mimetics (2016-01-12),

2. 8415298 - Administration of FGF2 for treamtent of anxiety (2013-04-09),

3. 8178299 - Method to determine the risk for side effects of an SSRI treatment in a person (2012-05-15),

4. 7951538 - Method to determine the risk for side effects of an SSRI treatment in a person (2011-05-31),

5. 7326697 - Methods for increasing the therapeutic response to electroconvulsive therapy (2008-02-05),

6. 7083921 - Method to determine the risk for side effects of an SSRI treatment in a person (2006-08-01),

7. 6680310 - Methods for preventing antipsychotic-induced weight gain (2004-01-20),

8. 6620802 - Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist (2003-09-16),

9. 6399310 - Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 (2002-06-04),

10. 6369046 - Methods for treating dementia (2002-04-09),

11. 6362173 - Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists (2002-03-26),

12. 6150349 - Methods for treating psychosis associated with glucocorticoid related (2000-11-21),

Title: Alan F Schatzberg: Innovator in Mental Health Treatments

Introduction

Alan F Schatzberg is a prominent inventor based in Los Altos, CA (US). He has made significant contributions to the field of mental health through his innovative research and patented inventions. With a total of 12 patents, Schatzberg has focused on developing methods for treating various mood disorders.

Latest Patents

Among his latest patents, Schatzberg has developed methods for treating depression using NCAM peptide mimetics. This invention relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder, and schizophrenia. It provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds useful for treating patients suffering from mental illness. Another significant patent involves the administration of FGF2 for the treatment of anxiety. This invention offers methods for diagnosing mental disorders and identifies modulators that can be used to treat patients experiencing these conditions.

Career Highlights

Schatzberg has had a distinguished career, working with reputable institutions such as Leland Stanford Junior University and Corcept Therapeutics Incorporated. His work has been instrumental in advancing the understanding and treatment of mental health disorders.

Collaborations

Throughout his career, Schatzberg has collaborated with notable colleagues, including Joseph K Belanoff and Greer M Murphy. These collaborations have further enriched his research and contributions to the field.

Conclusion

Alan F Schatzberg's innovative work in mental health treatment has made a lasting impact on the field. His patents and research continue to pave the way for new diagnostic and therapeutic approaches for mental disorders.

This text is generated by artificial intelligence and may not be accurate.